Sayenko Kharenko antitrust team has provided legal assistance to AbbVie Inc. in obtaining merger clearance with the Antimonopoly Committee of Ukraine for its acquisition of Allergan plc in a cash and stock transaction for an equity value of approximately USD 63 billion. The deal was successfully completed on 8 May 2020 following receipt of all necessary regulatory approvals.
AbbVie is a research-based global biopharmaceutical company committed to developing innovative, advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.
Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan has operations in more than 100 countries.
Sayenko Kharenko antitrust team advising AbbVie included partner Valentyna Hvozd, senior associate Anastasia Bodnar and associate Snizhanna Savka.